Sorafenib and metformin: to be, or not to be, that is the question.
作者信息
Orsi Giulia, Casadei-Gardini Andrea
机构信息
Division of Medical Oncology, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena, Modena, Italy.
出版信息
Hepatobiliary Surg Nutr. 2019 Aug;8(4):411-413. doi: 10.21037/hbsn.2019.04.01.
Abstract
摘要
相似文献
1
Sorafenib and metformin: to be, or not to be, that is the question.索拉非尼和二甲双胍：是，还是不是，这是个问题。
Hepatobiliary Surg Nutr. 2019 Aug;8(4):411-413. doi: 10.21037/hbsn.2019.04.01.
2
Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats.索拉非尼与阿托伐他汀以及索拉非尼与二甲双胍在大鼠体内的药代动力学相互作用
Pharmaceutics. 2020 Jun 28;12(7):600. doi: 10.3390/pharmaceutics12070600.
3
Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.二甲双胍可使索拉非尼在原位小鼠模型中更有效地抑制肝细胞癌术后复发和转移。
J Hematol Oncol. 2016 Mar 8;9:20. doi: 10.1186/s13045-016-0253-6.
4
Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.二甲双胍和索拉非尼对间变性甲状腺癌细胞及其干细胞生长的协同抗增殖作用。
Oncol Rep. 2015 Apr;33(4):1994-2000. doi: 10.3892/or.2015.3805. Epub 2015 Feb 16.
5
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.二甲双胍和胰岛素对接受索拉非尼治疗的晚期肝细胞癌患者临床结局的影响：验证研究及生物学原理
Eur J Cancer. 2017 Nov;86:106-114. doi: 10.1016/j.ejca.2017.09.003. Epub 2017 Oct 3.
6
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.二甲双胍对接受索拉非尼治疗的晚期肝癌糖尿病患者临床结局的影响。
Expert Opin Pharmacother. 2015;16(18):2719-25. doi: 10.1517/14656566.2015.1102887. Epub 2015 Oct 29.
7
Metformin reverses stem cell‑like HepG2 sphere formation and resistance to sorafenib by attenuating epithelial‑mesenchymal transformation.二甲双胍通过减弱上皮-间充质转化逆转了肝癌干细胞样 HepG2 球的形成和索拉非尼耐药性。
Mol Med Rep. 2018 Oct;18(4):3866-3872. doi: 10.3892/mmr.2018.9348. Epub 2018 Aug 3.
8
Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway.二甲双胍与索拉非尼联合通过靶向mTOR通路抑制肝癌细胞增殖并诱导自噬。
Int J Oncol. 2017 Jan;50(1):297-309. doi: 10.3892/ijo.2016.3799. Epub 2016 Dec 9.
9
Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.二甲双胍通过下调ERK/JNK介导的NF-κB依赖性途径抑制人肝癌细胞的侵袭，并增强对索拉非尼的化学敏感性，该途径可降低尿激酶型纤溶酶原激活剂（uPA）和基质金属蛋白酶-9（MMP-9）的表达。
Amino Acids. 2014 Dec;46(12):2809-22. doi: 10.1007/s00726-014-1838-4. Epub 2014 Sep 23.
10
Anti-tumoral effects of exercise on hepatocellular carcinoma growth.运动对肝细胞癌生长的抗肿瘤作用。
Hepatol Commun. 2018 Mar 22;2(5):607-620. doi: 10.1002/hep4.1159. eCollection 2018 May.
引用本文的文献
1
Fasting in combination with the cocktail Sorafenib:Metformin blunts cellular plasticity and promotes liver cancer cell death via poly-metabolic exhaustion.禁食联合索拉非尼与二甲双胍鸡尾酒疗法可通过多代谢耗竭抑制细胞可塑性并促进肝癌细胞死亡。
Cell Oncol (Dordr). 2025 Feb;48(1):161-182. doi: 10.1007/s13402-024-00966-2. Epub 2024 Jul 11.
2
Phosphorylated FOXQ1, a novel substrate of JNK1, inhibits sorafenib-induced ferroptosis by activating ETHE1 in hepatocellular carcinoma.磷酸化 FOXQ1 是 JNK1 的一种新型底物，通过激活肝细胞癌中的 ETHE1 抑制索拉非尼诱导的铁死亡。
Cell Death Dis. 2024 Jun 5;15(6):395. doi: 10.1038/s41419-024-06789-1.
3
Reduced Rates of Post-Transplant Recurrent Hepatocellular Carcinoma in Non-Alcoholic Steatohepatitis: A Propensity Score Matched Analysis.非酒精性脂肪性肝炎患者肝移植后复发肝细胞癌发生率降低：倾向评分匹配分析。
Transpl Int. 2022 Jul 5;35:10175. doi: 10.3389/ti.2022.10175. eCollection 2022.
4
Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians.非酒精性脂肪性肝病中的肝细胞癌——临床医生面临的新挑战综述
Hepatobiliary Surg Nutr. 2021 Jan;10(1):59-75. doi: 10.21037/hbsn.2019.08.08.
5
Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats.索拉非尼与阿托伐他汀以及索拉非尼与二甲双胍在大鼠体内的药代动力学相互作用
Pharmaceutics. 2020 Jun 28;12(7):600. doi: 10.3390/pharmaceutics12070600.
本文引用的文献
1
Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.非酒精性脂肪性肝病所致肝细胞癌的流行趋势。
Expert Rev Gastroenterol Hepatol. 2019 Feb;13(2):179-187. doi: 10.1080/17474124.2019.1549989. Epub 2018 Dec 29.
2
Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma.使用二甲双胍治疗与肝癌患者的生存延长有关。
Liver Int. 2019 Apr;39(4):714-726. doi: 10.1111/liv.14048. Epub 2019 Feb 7.
3
Synergistic effect of metformin on sorafenib in study using hepatocellular carcinoma cell lines.二甲双胍在使用肝癌细胞系的研究中对索拉非尼的协同作用。
Ann Hepatobiliary Pancreat Surg. 2018 Aug;22(3):179-184. doi: 10.14701/ahbps.2018.22.3.179. Epub 2018 Aug 31.
4
Metformin-associated Chemopreventive Effects on Recurrence After Hepatic Resection of Hepatocellular Carcinoma: From to a Clinical Study.二甲双胍对肝细胞癌肝切除术后复发的化学预防作用：从 到临床研究。 （你提供的原文中“From to”部分信息不完整，请检查补充完整以便能更准确翻译。）
Anticancer Res. 2018 Apr;38(4):2399-2407. doi: 10.21873/anticanres.12490.
5
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.二甲双胍和胰岛素对接受索拉非尼治疗的晚期肝细胞癌患者临床结局的影响：验证研究及生物学原理
Eur J Cancer. 2017 Nov;86:106-114. doi: 10.1016/j.ejca.2017.09.003. Epub 2017 Oct 3.
6
Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma.SIRT-3、代谢及其在肝细胞癌中的肿瘤抑制作用之间的相互作用
Dig Dis Sci. 2017 Aug;62(8):1872-1880. doi: 10.1007/s10620-017-4615-x. Epub 2017 May 19.
7
Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway.二甲双胍与索拉非尼联合通过靶向mTOR通路抑制肝癌细胞增殖并诱导自噬。
Int J Oncol. 2017 Jan;50(1):297-309. doi: 10.3892/ijo.2016.3799. Epub 2016 Dec 9.
8
Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma.系统评价与网络荟萃分析：抗糖尿病药物与肝细胞癌风险。
Sci Rep. 2016 Sep 19;6:33743. doi: 10.1038/srep33743.
9
Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection: A Nationwide Population-Based Study.根治性切除术后肝细胞癌患者使用二甲双胍与癌症特异性死亡率的关联：一项基于全国人群的研究。
Medicine (Baltimore). 2016 Apr;95(17):e3527. doi: 10.1097/MD.0000000000003527.
10
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.二甲双胍对接受索拉非尼治疗的晚期肝癌糖尿病患者临床结局的影响。
Expert Opin Pharmacother. 2015;16(18):2719-25. doi: 10.1517/14656566.2015.1102887. Epub 2015 Oct 29.
Zotero 插件